Perrigo Company PLC officially reaches the finish line on becoming a manufacturer entirely focused on consumer health product with the closing of its $1.55bn deal to divest its generic Rx product business to Altaris Capital Partners LLC.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?